Results from Bristol-Myers Squibb Co.. and Ono Pharmaceutical Co. Ltd.’s Phase III ATTRACTION-3 trial showed Opdivo (nivolumab) ‘significantly’ extended overall survival (OS) compared with chemotherapy in patients with previously treated advanced esophageal squamous cell carcinoma, enhancing the PD-1 inhibitor’s likelihood of approval in that indication.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?